|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM072321679 |
| 003 |
DE-627 |
| 005 |
20231222013951.0 |
| 007 |
tu |
| 008 |
231222s1981 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0241.xml
|
| 035 |
|
|
|a (DE-627)NLM072321679
|
| 035 |
|
|
|a (NLM)7255511
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hemming, J D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Bioavailability of aspirin in the presence of dextropropoxyphene/paracetamol combination
|
| 264 |
|
1 |
|c 1981
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.09.1981
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The effect of 2 doses of a combination analgesic preparation (each dose containing 65 mg dextropropoxyphene hydrochloride and 650 mg paracetamol) upon plasma salicylate concentration after a single dose of soluble aspirin (1.2 g) or enteric-coated aspirin (1.2 g) was examined in 6 normal volunteers and compared with the effect of placebo. The dextropropoxyphene/paracetamol caused no reduction in the plasma salicylate level after absorption of soluble aspirin compared with placebo and, although a reduction in plasma salicylate was seen after enteric-coated aspirin in a single subject, this may reflect erratic absorption rather than a drug interaction
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Controlled Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Acetaminophen
|2 NLM
|
| 650 |
|
7 |
|a 362O9ITL9D
|2 NLM
|
| 650 |
|
7 |
|a acetaminophen, dextropropoxyphene, drug combination
|2 NLM
|
| 650 |
|
7 |
|a 39400-85-6
|2 NLM
|
| 650 |
|
7 |
|a Aspirin
|2 NLM
|
| 650 |
|
7 |
|a R16CO5Y76E
|2 NLM
|
| 650 |
|
7 |
|a Dextropropoxyphene
|2 NLM
|
| 650 |
|
7 |
|a S2F83W92TK
|2 NLM
|
| 700 |
1 |
|
|a Bird, H A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pickup, M E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saunders, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lowe, J R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dixon, J S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 2(1981), 8 vom: 16., Seite 543-6
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:2
|g year:1981
|g number:8
|g day:16
|g pages:543-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 2
|j 1981
|e 8
|b 16
|h 543-6
|